Le Tuan Dinh, Nguyen Nga Thi Phi, Nguyen Son Tien, Tran Hoa Thi Thanh, Nguyen Lan Thi Ho, Duong Hoang Huy, Nguyen Ha Manh, Do Binh Nhu
Department of Internal Medicine, Thai Binh University of Medicine and Pharmacy, Thai Binh, Vietnam.
Department of Endocrinology, Military Hospital 103, Ha Noi, Vietnam.
Diabetes Metab Syndr Obes. 2020 Jun 19;13:2119-2127. doi: 10.2147/DMSO.S255071. eCollection 2020.
To investigate effects of Sitagliptin on the enhancement of beta-cell function, reducing insulin resistance, serum glucagon like peptide-1 (GLP-1) concentrations and blood glucose in patients with type 2 diabetes mellitus (T2D) and suggest one of the underlying mechanisms on beta-cell function and insulin resistance.
This was a cross-sectional and observational study in comparison to the control group. A study population of 44 newly diagnosed patients with T2D treated with Sitagliptin with a dose of 100 mg/day for 3 months was analyzed to compare 52 healthy participants. Indices for beta-cell function, peripheral insulin sensitivity, and insulin resistance were calculated with homeostasis model assessment 2 (HOMA2) calculator and compared. Serum GLP-1 concentrations were analyzed, and regression analysis was conducted to find the correlations between GLP-1 and beta-cell function and insulin resistance.
Newly diagnosed patients with T2D witnessed a significant reduction in beta-cell function, serum GLP-1 concentrations at the time of diagnosis. After treatment with Sitagliptin 100 mg/day, they achieved significant improvements in beta-cell function, peripheral insulin sensitivity and insulin resistance. Serum GLP-1 concentrations were increased significantly to those levels in the control group and correlated with peripheral insulin sensitivity and insulin resistance in patients whose beta-cell functions improved.
Sitagliptin improved beta-cell function, insulin resistance and blood glucose in newly diagnosed patients with T2D. Meanwhile, Sitagliptin ameliorated serum GLP-1 concentrations, which contributed to the enhancement of beta-cell.
探讨西格列汀对2型糖尿病（T2D）患者β细胞功能增强、胰岛素抵抗降低、血清胰高血糖素样肽-1（GLP-1）浓度及血糖的影响，并提出其对β细胞功能和胰岛素抵抗的潜在作用机制之一。
这是一项与对照组比较的横断面观察性研究。分析了44例新诊断的T2D患者，他们接受剂量为100mg/天的西格列汀治疗3个月，以与52名健康参与者进行比较。使用稳态模型评估2（HOMA2）计算器计算β细胞功能、外周胰岛素敏感性和胰岛素抵抗指标并进行比较。分析血清GLP-1浓度，并进行回归分析以发现GLP-1与β细胞功能和胰岛素抵抗之间的相关性。
新诊断的T2D患者在诊断时β细胞功能、血清GLP-1浓度显著降低。在接受100mg/天西格列汀治疗后，他们的β细胞功能、外周胰岛素敏感性和胰岛素抵抗有显著改善。血清GLP-1浓度显著升高至对照组水平，并与β细胞功能改善患者的外周胰岛素敏感性和胰岛素抵抗相关。
西格列汀改善了新诊断的T2D患者的β细胞功能、胰岛素抵抗和血糖。同时，西格列汀改善了血清GLP-1浓度，这有助于β细胞功能的增强。
